


## GSK2983559 free acid

<b>Cat. No.:</b>	HY-112038		
<b>CAS No.:</b>	1579965-12-0		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>23</sub> N <sub>4</sub> O <sub>7</sub> PS <sub>2</sub>		
<b>Molecular Weight:</b>	538.53		
<b>Target:</b>	RIP kinase		
<b>Pathway:</b>	Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 5 mg/mL (9.28 mM; ultrasonic and warming and heat to 80°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.8569 mL	9.2845 mL	18.5691 mL
5 mM	0.3714 mL	1.8569 mL	3.7138 mL
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

GSK2983559 free acid (compound 3) is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 free acid can block many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

RIPK2

#### In Vitro

GSK2983559 (1-1024 nM; 2 h) blocks MDP-induced IL-8 in THP-1 cells<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[2]</sup>

Cell Line: THP-1 cells

Concentration: 1-1024 nM

Incubation Time: 2 hours

	Result:	Inhibited IL-8 production with an IC <sub>50</sub> of 1.34 nM.
<b>In Vivo</b>	GSK2983559 (oral gavage; 3 and 10 mg/kg; once) inhibits effectively MDP-induced IL-6 in mouse <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	C57BL/6 mice (female) injected with MDP (100 µg) <sup>[2]</sup>
	Dosage:	3 and 10 mg/kg
	Administration:	Oral gavage; 3 and 10 mg/kg; once
	Result:	Suppressed serum IL-6 levels in a dose-dependent manner.

## REFERENCES

[1]. Shuwei Wu, et al. Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors. *Bioorg Med Chem Lett*. 2022 Sep 2;75:128968.

[2]. Haile PA, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammation

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA